Ocugen to Participate in a Virtual Fireside Chat at the Chardan Genetic Medicines Conference
29 September 2020 - 9:35PM
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on
discovering, developing, and commercializing transformative
therapies to cure blindness diseases, today announced it will
participate in a Virtual Fireside Chat during the Chardan Genetic
Medicines Conference on October 6th at 9 a.m.
Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder along with
Dr. Mohamed Genead, M.D., Acting Chief Medical Officer, will
discuss the advantages of Ocugen’s Modifier Gene Therapy Platform
and provide an overview of the preclinical results using NR2E3 as a
genetic modifier that was published earlier this year in Nature
Gene Therapy. In addition, Drs. Musunuri and Genead will discuss
planning around the initiation of their Phase 1/2a studies in 2021
for OCU400 including an update on scale-up manufacturing of
clinical supplies with CanSinoBIO. OCU400 is a novel gene therapy
product candidate with the potential to be broadly effective in
restoring retinal integrity and function across a range of
genetically diverse inherited retinal diseases. They will also
discuss other business progress including OCU200 program.
Presentation Details:
Conference: Chardan
Genetic Medicines ConferenceFormat:
Fireside ChatDate: Tuesday, October 6,
2020Time: 9:00 AM (Eastern Time)Webcast
Link:
https://wsw.com/webcast/chard6/ocgn/1842984
The Chardan Genetic Medicines Conference will
take place on October 5-6.
About Ocugen, Inc.Ocugen, Inc. is a
biopharmaceutical company focused on discovering, developing, and
commercializing transformative therapies to cure blindness
diseases. Our breakthrough modifier gene therapy platform has the
potential to treat multiple retinal diseases with one drug – “one
to many” and our novel biologic product candidate aims to offer
better therapy to patients with underserved diseases such as wet
age-related macular degeneration, diabetic macular edema, and
diabetic retinopathy. For more information, please visit
www.ocugen.com.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from our current expectations. These and other risks and
uncertainties are more fully described in our periodic filings with
the Securities and Exchange Commission (the “SEC”), including the
risk factors described in the section entitled “Risk Factors” in
the quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events or otherwise, after the date of this
press release.
Corporate Contact:Ocugen,
Inc.Sanjay SubramanianChief Financial
Officerir@ocugen.comMedia
Contact:LaVoieHealthScienceKatie
Gallagherkgallagher@lavoiehealthscience.com+1 617-792-3937
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2024 to May 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From May 2023 to May 2024